Valproate safety information

The Medicines and Healthcare products Regulatory Agency (MHRA) have published a Drug Safety Update and updated safety and educational materials to support healthcare professionals and patients to implement the existing regulatory requirements. 

The updates reflect:

• precautionary advice on the potential risk of neurodevelopmental disorders in children fathered by men taking valproate around the time of conception
• a risk of lower weight at birth for the gestational age in children exposed to valproate during pregnancy

For more information follow this link to the GPhC website.